(1R,4R)-4-phenylcyclopent-2-enol | 913715-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,4R)-4-phenylcyclopent-2-enol
• 英文别名: (1R,4R)-4-phenylcyclopent-2-en-1-ol
• CAS: 913715-19-2
• 化学式: C₁₁H₁₂O
• 分子量: 160.216
• InChiKey: IYAPEWJVBBMQTF-QWRGUYRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1R,4R)-4-phenylcyclopent-2-enol 生成 (1S,2S,4R,5R)-4-phenyl-6-oxabicyclo[3.1.0]hexan-2-ol
  参考文献：
  名称：

  MARINO, JOSEPH P.;FERNANDEZ, DE LA PRADILLA ROBERTO;LABORDE, EDGARDO, J. ORG. CHEM., 52,(1987) N 22, 4898-4913

  摘要：

  DOI：
• 作为产物：
  描述：

  6-噁双环[3.1.0]-3-己烯 生成 (1R,4R)-4-phenylcyclopent-2-enol
  参考文献：
  名称：

  MARINO, JOSEPH P.;FERNANDEZ, DE LA PRADILLA ROBERTO;LABORDE, EDGARDO, J. ORG. CHEM., 52,(1987) N 22, 4898-4913

  摘要：

  DOI：

文献信息

• TRPV1 Antagonists
  申请人：Gomtsyan Arthur

  公开号：US20120245163A1

  公开（公告）日：2012-09-27

  Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X 1 , X 2 , X 3 , X 4 , J, K, L, X 5 , X 6 , R b , G 2 , and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了具有以下式（I）的化合物或药用可接受的盐、溶剂或其组合物，其中X1、X2、X3、X4、J、K、L、X5、X6、Rb、G2和m在规范中有定义。还披露了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。
• Concise synthesis of trans- and cis-3,4-disubstituted piperidines based on regio- and stereoselective allylation of cyclopentenyl esters
  作者：Junji Igarashi、Hiroyuki Ishiwata、Yuichi Kobayashi

  DOI：10.1016/j.tetlet.2004.08.174

  日期：2004.10

  3,4-Disubstituted piperidines were synthesized through anti SN2′ allylation of 4-substituted 2-cyclopentenyl esters with reagents based on RMgX and CuX, thus allowing equal access to both trans- and cis-isomers. As an application, the paroxetine intermediate was synthesized efficiently. During the investigation, the MeOCH2CO2 group was found to show high reactivity in the pivotal anti SN2′ type reaction

  3,4-二取代的哌啶是通过抗小号合成Ñ 2'的具有基于RMGX和的CuX试剂4-取代的2-环戊烯基酯烯丙基化，从而允许两者相等访问反式-和顺式-异构体。作为一种应用，高效合成了帕罗西汀中间体。在研究过程中，发现使用（i -PrO）Me 2 SiCH 2 MgCl和CuCN衍生的试剂，MeOCH 2 CO 2基团在关键的反S N 2'型反应中显示出高反应活性。
• TRPV1 antagonists
  申请人：Gomtsyan Arthur

  公开号：US08802711B2

  公开（公告）日：2014-08-12

  Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了公式（I）的化合物或其药学上可接受的盐，溶剂化合物或其组合物，其中X1、X2、X3、X4、J、K、L、X5、X6、Rb、G2和m在规范中定义。还揭示了包含这样的化合物的组合物以及使用这样的化合物和组合物治疗疾病和疾病的方法。
• Rhodium-Catalyzed Asymmetric Allylic Substitution with Boronic Acid Nucleophiles
  作者：Frederic Menard、Timothy M. Chapman、Chris Dockendorff、Mark Lautens

  DOI：10.1021/ol061777l

  日期：2006.9.1

  An enantio-, regio-, and diastereoselective rhodium(I)-catalyzed desymmetrization of a meso-cyclic allylic dicarbonate with organoboronic acid nucleophiles is described. The rhodium(I) catalyst formed in situ from [Rh(cod)OH](2) and Xyl-P-PHOS allowed the S(N)2' allylic substitution product to be obtained with a range of arylboronic acids in enantiomeric excesses of up to 92% with regioselectivities of up to > 20:1.
• TUETING, DAVID R.;ECHAVARREN, ANTONIO M.;STILLE, J. K., TETRAHEDRON, 45,(1989) N, C. 979-992
  作者：TUETING, DAVID R.、ECHAVARREN, ANTONIO M.、STILLE, J. K.

  DOI：——

  日期：——